当前位置：药药网 / 医药文献 /临床试验研究设计终点和生物标志物药物安全性(本栏目收费,不能显示细节,电话13136136841)
关键字：
类型：
下载页码(大于等于0,小于611)：
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
临床试验研究设计终点和生物标志物药物安全性 890条(本栏目收费,不能显示细节,电话13136136841)
Drug resistance ABC transporters,76–77 77
cross-resistance,77–78 78
ECOG performance status,73–74 74
EDSS see Expanded Disability Status Scale Elixir Sulfanilamide,578–579 579
Endpoints clinical endpoint,191 191
hematological cancers event-free survival,311–313 313
relapse-free interval,313 313
mechanism of action and surrogate endpoints,473 473
multiple endpoints,194–195 195
relatively objective endpoints versus relatively subjective endpoints,193–194 194
supportive care and health-related quality of life endpoint conflict,136 136
surrogate endpoint,191–192 192
Blinding allocation concealment versus blinding,112–113 113
Blood cancers see Hematological cancers Blumenschein schema,28–30 30